CAC
SCPH

Cowen and Company’s scPharmaceuticals SCPH Stock Holding History

Cowen and Company’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,795,647
Closed -$12.8M – 658
2023
Q3 		$12.8M Sell
1,795,647
-42,271
-2% -$333K 0.89% 27
2023
Q2 		$18.7M Sell
1,837,918
-969,644
-35% -$10.1M 1.55% 15
2023
Q1 		$25.5M Buy
+2,807,562
New +$20.6M 2.99% 6

Other funds holding SCPH

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $23.1B AUM 21.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Cowen and Company's SCPH Position: Q4 2023 in Review

Cowen and Company sold out of scPharmaceuticals (SCPH) in Q4 2023, closing a stake of 1,795,647 shares — an estimated $12.8M sold.

Cowen and Company first reported a position in SCPH in Q1 2023 and held it in 3 quarters. The position peaked at $25.5M in Q1 2023. 81 funds tracked by Wall St. Rank hold SCPH as of Q4 2023.

  • Cowen and Company reported no remaining scPharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Cowen and Company sold 1,795,647 scPharmaceuticals shares in Q4 2023, an estimated $12.8M.
  • Cowen and Company first reported a position in scPharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Cowen and Company's scPharmaceuticals position peaked at $25.5M in Q1 2023.
  • 81 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2023.

Based on Cowen and Company's 13F filing for Q4 2023, filed 8 Feb 2024.